ONCS | OncoSec Medical Incorporated Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2520 - 0.3968
52 Week Range	0.1800 - 20.46
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	51,295,233
Average Volume	2,131,119
Shares Outstanding	5,962,560
Market Cap	1,652,822
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-04-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-20.31
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	40
Country	USA
Website	ONCS

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

ONCS's peers: SPRC

*Chart delayed

Analyzing fundamentals for ONCS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ONCS Fundamentals page.

Watching at ONCS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ONCS Technicals page.